Back to School: How biopharma can reboot drug development. Access exclusive analysis here

End of the road for Merck's anacetrapib

Merck & Co. Inc. (NYSE:MRK) said it will not seek regulatory approval of anacetrapib (MK-0859)

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE